Jiangsu Sihuan Bioengineering Co., Ltd (SHE:000518)
China · Delayed Price · Currency is CNY 3.100
-0.060 (-1.90%)
Nov 6, 2026, 9:35 AM CST
SHE:000518 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 278.89 | 339.42 | 195.87 | 229.61 | 261.99 | 344.49 |
Other Revenue | 4.97 | 4.97 | 7.65 | 5.81 | 8.16 | 6.47 |
| 283.86 | 344.38 | 203.52 | 235.42 | 270.15 | 350.96 | |
Revenue Growth | -16.97% | 69.22% | -13.55% | -12.86% | -23.03% | -30.56% |
Cost of Revenue | 236.3 | 222.16 | 113.41 | 88.08 | 86.36 | 115.11 |
Gross Profit | 47.56 | 122.23 | 90.11 | 147.34 | 183.79 | 235.85 |
Selling, General & Admin | 96.87 | 122.75 | 127.33 | 182.46 | 187.13 | 211.48 |
Research & Development | 23.44 | 32.48 | 29.01 | 29.15 | 38.97 | 51.84 |
Other Operating Expenses | 2.55 | 1.55 | 1.42 | 1.37 | 2.08 | 2.2 |
Operating Expenses | 128.38 | 166.43 | 158.4 | 214.55 | 233.34 | 271.01 |
Operating Income | -80.82 | -44.2 | -68.29 | -67.21 | -49.56 | -35.16 |
Interest Expense | -0.3 | -1.69 | -2.12 | -2.46 | -0.72 | -0.7 |
Interest & Investment Income | 2.03 | 3.59 | 0.49 | 1.8 | 0.08 | 0.11 |
Currency Exchange Gain (Loss) | -0.04 | -0.04 | 0.05 | 0.08 | 0.32 | -0.03 |
Other Non Operating Income (Expenses) | -3.3 | -0.14 | 0.32 | -4.82 | -2.23 | -2.34 |
EBT Excluding Unusual Items | -82.42 | -42.47 | -69.55 | -72.62 | -52.11 | -38.11 |
Gain (Loss) on Sale of Investments | -0.05 | -0.03 | 0.04 | -0.02 | -0.26 | -0.54 |
Gain (Loss) on Sale of Assets | -0.07 | 0.76 | 2.41 | -0.02 | - | 0.21 |
Asset Writedown | 1.28 | -0.61 | -15.31 | -4 | -2.26 | - |
Legal Settlements | -0.22 | -0.22 | -8.26 | -2.85 | - | - |
Other Unusual Items | 2.53 | 1.65 | -23.05 | 0.09 | 1.03 | 2.42 |
Pretax Income | -78.95 | -40.92 | -113.73 | -79.43 | -53.61 | -36.04 |
Income Tax Expense | -0.67 | -1.31 | 0.07 | 0.99 | -0.33 | 2.24 |
Earnings From Continuing Operations | -78.28 | -39.61 | -113.81 | -80.41 | -53.28 | -38.27 |
Minority Interest in Earnings | 5.38 | 2.52 | 3.81 | 5.14 | 4.49 | 3.48 |
Net Income | -72.9 | -37.09 | -109.99 | -75.27 | -48.79 | -34.79 |
Net Income to Common | -72.9 | -37.09 | -109.99 | -75.27 | -48.79 | -34.79 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 1,029 | 1,030 | 1,030 | 1,030 | 1,029 | 1,029 |
Shares Outstanding (Diluted) | 1,029 | 1,030 | 1,030 | 1,030 | 1,029 | 1,029 |
Shares Change | -0.34% | 0.04% | 0.02% | 0.03% | 0.01% | -0.07% |
EPS (Basic) | -0.07 | -0.04 | -0.11 | -0.07 | -0.05 | -0.03 |
EPS (Diluted) | -0.07 | -0.04 | -0.11 | -0.07 | -0.05 | -0.03 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Free Cash Flow | -36.05 | 74.52 | -4.1 | -6.56 | -3.61 | -7.53 |
Free Cash Flow Per Share | -0.04 | 0.07 | -0.00 | -0.01 | -0.00 | -0.01 |
Gross Margin | 16.75% | 35.49% | 44.27% | 62.59% | 68.03% | 67.20% |
Operating Margin | -28.47% | -12.83% | -33.56% | -28.55% | -18.34% | -10.02% |
Profit Margin | -25.68% | -10.77% | -54.05% | -31.97% | -18.06% | -9.91% |
Free Cash Flow Margin | -12.70% | 21.64% | -2.01% | -2.79% | -1.34% | -2.15% |
EBITDA | -72.75 | -32.76 | -52.35 | -47.97 | -29.91 | -16.4 |
EBITDA Margin | -25.63% | -9.51% | -25.72% | -20.38% | -11.07% | -4.67% |
D&A For EBITDA | 8.07 | 11.44 | 15.94 | 19.25 | 19.64 | 18.76 |
EBIT | -80.82 | -44.2 | -68.29 | -67.21 | -49.56 | -35.16 |
EBIT Margin | -28.47% | -12.83% | -33.56% | -28.55% | -18.34% | -10.02% |
Revenue as Reported | 50.01 | 344.38 | 203.52 | 235.42 | 270.15 | 350.96 |
Advertising Expenses | - | - | - | 0.18 | 116.01 | 135.3 |